257 related articles for article (PubMed ID: 30318842)
1. Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals.
McKinnon K; Jupp J; Ghosh S; Digout C; Eason S; Romanick M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27488. PubMed ID: 30318842
[TBL] [Abstract][Full Text] [Related]
2. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
3. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group.
Araz M; Karaagac M; Korkmaz L; Beypinar I; Uysal M
Curr Probl Cancer; 2019 Aug; 43(4):344-353. PubMed ID: 30497851
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.
Gilmore JW; Peacock NW; Gu A; Szabo S; Rammage M; Sharpe J; Haislip ST; Perry T; Boozan TL; Meador K; Cao X; Burke TA
J Oncol Pract; 2014 Jan; 10(1):68-74. PubMed ID: 24065402
[TBL] [Abstract][Full Text] [Related]
5. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan.
Baba Y; Baba H; Yamamoto S; Shimada H; Shibata T; Miyazaki T; Yoshikawa T; Nakajima Y; Tsuji Y; Shimokawa M; Kitagawa Y; Aiba K
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 27001532
[TBL] [Abstract][Full Text] [Related]
7. Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data.
Aapro M; Scotté F; Escobar Y; Celio L; Berman R; Franceschetti A; Bell D; Jordan K
Oncologist; 2021 Jun; 26(6):e1073-e1082. PubMed ID: 33555084
[TBL] [Abstract][Full Text] [Related]
8. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China.
Sun Y; Zheng Y; Yang X; Xie K; Du C; He L; Gui Y; Fu J; Li C; Zhang H; Zhu L; Bie J; Sun Y; Fu Y; Zhou Y; Shou F; Wang Y; Zhu J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2701-2708. PubMed ID: 33586045
[TBL] [Abstract][Full Text] [Related]
9. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.
Dielenseger P; Börjeson S; Vidall C; Young A; Jahn P
Support Care Cancer; 2019 Nov; 27(11):4099-4106. PubMed ID: 30783815
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2017 Apr; 22(2):405-412. PubMed ID: 27909835
[TBL] [Abstract][Full Text] [Related]
12. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
Navari RM; Ruddy KJ; LeBlanc TW; Nipp R; Clark-Snow R; Schwartzberg L; Binder G; Bailey WL; Potluri R; Schmerold LM; Papademetriou E; Roeland EJ
Oncologist; 2021 Apr; 26(4):325-331. PubMed ID: 33289268
[TBL] [Abstract][Full Text] [Related]
13. Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study.
Lee MA; Cho EK; Oh SY; Ahn JB; Lee JY; Thomas B; Jung H; Kim JG
Cancer Res Treat; 2016 Oct; 48(4):1420-1428. PubMed ID: 26875197
[TBL] [Abstract][Full Text] [Related]
14. Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients.
Kacar M; MacDonald P; Gibson P
Pediatr Blood Cancer; 2023 Apr; 70(4):e30210. PubMed ID: 36642973
[TBL] [Abstract][Full Text] [Related]
15. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy.
Chasen M; Urban L; Schnadig I; Rapoport B; Powers D; Arora S; Navari R; Schwartzberg L; Gridelli C
Support Care Cancer; 2017 Jan; 25(1):85-92. PubMed ID: 27557833
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced nausea and vomiting in patients with breast cancer: a prospective cohort study.
Naito Y; Kai Y; Ishikawa T; Fujita T; Uehara K; Doihara H; Tokunaga S; Shimokawa M; Ito Y; Saeki T
Breast Cancer; 2020 Jan; 27(1):122-128. PubMed ID: 31407150
[TBL] [Abstract][Full Text] [Related]
17. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics.
Grunberg SM; Deuson RR; Mavros P; Geling O; Hansen M; Cruciani G; Daniele B; De Pouvourville G; Rubenstein EB; Daugaard G
Cancer; 2004 May; 100(10):2261-8. PubMed ID: 15139073
[TBL] [Abstract][Full Text] [Related]
18. Antiemetic Guidelines: Using Education to Improve Adherence and Reduce Incidence of CINV in Patients Receiving Highly Emetogenic Chemotherapy.
Mellin C; Lexa M; Leak Bryant A; Mason S; Mayer DK
Clin J Oncol Nurs; 2018 Jun; 22(3):297-303. PubMed ID: 29781466
[TBL] [Abstract][Full Text] [Related]
19. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
20. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.
Bloechl-Daum B; Deuson RR; Mavros P; Hansen M; Herrstedt J
J Clin Oncol; 2006 Sep; 24(27):4472-8. PubMed ID: 16983116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
